What are the indications for Lucius version of the generic version of pemetinib and how to use it correctly?

In the field of cancer treatment, the emergence of targeted drugs has brought new hope to patients. Pemigatinib (Pemigatinib), as a small molecule kinase inhibitor targeting the FGFR (fibroblast growth factor receptor) pathway, its generic version is produced by Lucius Pharmaceuticals (Laos) Co., Ltd., at an affordable price, providing great economic relief for patients who require long-term treatment. Below, we will introduce in detail the indications and medication guidance of the Lucius version of the generic version of pemetinib.

1. Overview of indications

The Lucius version of the generic version of pemetinib is mainly targeted at two types of cancer patients:

1. Cholangiocarcinoma patients: For adult patients with previously treated but unresectable locally advanced or metastatic cholangiocarcinoma, if their tumors are confirmed to have FGFR2 fusions or other rearrangements, the Lucius version of pemetinib will be an effective treatment option. By precisely inhibiting the activity of FGFR2, the drug can block the growth signals of tumor cells, thereby helping to prolong the survival of patients and significantly improve their quality of life.

2. Myeloid/Lymphoid tumor patients: For patients with relapsed or refractory myeloid/lymphoid tumors (MLNs) carrying FGFR1 rearrangements, the Lucius version of pemetinib has also shown good therapeutic effects. It can effectively inhibit the activity of FGFR1, thereby inhibiting the growth and spread of tumor cells, providing a new treatment path for patients.

2. Detailed medication guidance

1. Dosage and usage:

1) Cholangiocarcinoma: It is recommended that adult patients take 13.5 mg daily for 14 consecutive days and then stop for 7 days, forming a 21-day treatment cycle. This cycle should be continued until disease progression or unacceptable toxicity occurs.

2) Myeloid/Lymphoid neoplasms: Similarly, the usual dose for adult patients is 13.5 mg orally per day, with continued treatment until disease progression or unacceptable toxicity.

2. How to take: Pemetinib tablets should be swallowed whole and avoid chewing, crushing or dissolving. Patients can choose to take it with or without food, but should maintain consistent daily dosing times. If you miss a dose and it is more than 4 hours before the next dose, you do not need to take a make-up dose and continue taking the next dose according to the normal schedule.

3. Monitoring and follow-up: During treatment, patients should regularly receive monitoring of hematological and biochemical indicators, such as liver function, blood phosphorus levels, etc., in order to promptly detect and deal with any possible adverse reactions. At the same time, patients should pay close attention to changes in their physical condition and report any discomfort or abnormal reactions to their doctor immediately.

4. Precautions: Patients should avoid drinking alcohol while using pemetinib, because alcohol may affect the metabolism and efficacy of the drug. In addition, patients should proactively inform their doctors about all medications they are currently taking, including prescription drugs, over-the-counter drugs, and supplements, to ensure that adverse drug interactions do not occur.

In summary, Lucius generic version of pemetinib provides an affordable and effective treatment option for cancer patients with specific genetic mutations. However, patients must strictly abide by medical instructions and medication instructions during medication to ensure the safety and effectiveness of the medication. At the same time, when purchasing drugs overseas, you need to carefully choose formal and legal channels to ensure drug safety.